United States Biotechnology & Medical Research

ANI Pharmaceuticals Inc (ANIP)

Track

Over the past 90 days, ANI Pharmaceuticals Inc. insiders have executed 21 transactions, all of which were sales totaling approximately $15.18 million. Key executives, including the CFO and General Counsel, have consistently offloaded shares. These transactions follow the company's May 2026 results financiers, where the firm reported an earnings beat.
Ticker: ANIP Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for ANI Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 29 Jul 2026
Value US$1,138,774.77 | Price 131.85 | Shares 70,056 (-34.8%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-30 2026-07-29 PlS Planned sale
2.8
CAREY STEPHEN P.

SVP & CFO

Officer
70,056 -34.8%
131.85
US$1,138,775 		70,056 -34.8% 131.85 US$1,138,775
2026-07-29 2026-07-29 PrS Proposed sale
2.8
STEPHEN P CAREY

Officer

Officer
85,432
10.91
US$4,105,607 		85,432 10.91 US$4,105,607
2026-07-14 2026-07-13 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
52,090 +29.2%
11.61
US$2,241,106 		52,090 +29.2% 11.61 US$2,241,106
2026-07-07 2026-07-07 PrS Proposed sale
3.8
PATRICK WALSH

Director

Non-Executive Director
4,336
86.19
US$373,720 		4,336 86.19 US$373,720
2026-07-06 2026-07-02 PlS Planned sale
2.8
CAREY STEPHEN P.

SVP & CFO

Officer
3,313 -1.8%
86.00
US$284,918 		3,313 -1.8% 86.00 US$284,918
2026-06-30 2026-06-29 PlS Planned sale
2.8
CAREY STEPHEN P.

SVP & CFO

Officer
2,850 -1.6%
84.12
US$239,742 		2,850 -1.6% 84.12 US$239,742
2026-06-15 2026-06-12 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
500 -0.6%
82.03
US$41,015 		500 -0.6% 82.03 US$41,015
2026-06-10 2026-06-08 PlS Planned sale
2.6
HAUGHEY THOMAS
Non-Executive Director
2,000 -4.9%
80.88
US$161,760 		2,000 -4.9% 80.88 US$161,760
2026-06-10 2026-06-08 PlS Planned sale
2.6
HAUGHEY THOMAS
Non-Executive Director
2,000 -4.9%
80.88
US$161,760 		2,000 -4.9% 80.88 US$161,760
2026-06-08 2026-06-08 PrS Proposed sale
2.6
THOMAS HAUGHEY

Director

Non-Executive Director
2,000
81.11
US$162,220 		2,000 81.11 US$162,220
2026-06-09 2026-06-05 PlS Planned sale
2.8
CAREY STEPHEN P.

SVP & CFO

Officer
3,312 -1.8%
80.00
US$264,960 		3,312 -1.8% 80.00 US$264,960
2026-06-05 2026-06-05 PrS Proposed sale
2.8
STEPHEN P CAREY

Officer

Officer
11,862
79.20
US$939,470 		11,862 79.20 US$939,470
2026-06-05 2026-06-05 PrS Proposed sale
2.8
STEPHEN P CAREY

Officer

Officer
11,862
79.20
US$939,470 		11,862 79.20 US$939,470
2026-05-13 2026-05-13 S Sale
3.8
Walsh Patrick D
Non-Executive Director
10,000 -20.6%
80.63
US$806,300 		10,000 -20.6% 80.63 US$806,300
2026-05-13 2026-05-13 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
500 -0.6%
78.16
US$39,080 		500 -0.6% 78.16 US$39,080
2026-05-13 2026-05-13 PrS Proposed sale
3.8
Walsh Patrick D

Director

Non-Executive Director
10,000
79.56
US$795,600 		10,000 79.56 US$795,600
2026-05-13 2026-05-12 S Sale
1.0
Rowland Thomas Andrew

SVP, HEAD - ESTABLISHED BRANDS

Officer
459 -1.2%
79.21
US$36,357 		459 -1.2% 79.21 US$36,357
2026-05-13 2026-05-12 S Sale
3.2
Gutwerg Ori

SVP, GENERICS

Officer
2,772 -3.4%
79.50
US$220,374 		2,772 -3.4% 79.50 US$220,374
2026-05-13 2026-05-11 S Sale
3.8
Walsh Patrick D
Non-Executive Director
3,973 -7.6%
80.75
US$320,820 		3,973 -7.6% 80.75 US$320,820
2026-05-13 2026-05-11 S Sale
3.0
Lalwani Nikhil

PRESIDENT & CEO

Executive Director
55,000 -13.6%
77.57
US$4,266,350 		55,000 -13.6% 77.57 US$4,266,350
2026-05-11 2026-05-11 PrS Proposed sale
3.0
NIKHIL LALWANI

Officer; Director

Executive Director
55,000
77.57
US$4,266,564 		55,000 77.57 US$4,266,564
2026-05-11 2026-05-11 PrS Proposed sale
3.8
PATRICK WALSH

Director

Non-Executive Director
3,973
80.75
US$320,820 		3,973 80.75 US$320,820
2026-04-13 2026-04-13 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
500 -0.6%
77.95
US$38,975 		500 -0.6% 77.95 US$38,975
2026-03-13 2026-03-13 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
500 -0.6%
72.62
US$36,310 		500 -0.6% 72.62 US$36,310
2026-03-13 2026-03-13 PlS Planned sale
2.5
Mutz Christopher

HEAD OF RARE DISEASE

Officer
3,162 -3.3%
71.64
US$226,526 		3,162 -3.3% 71.64 US$226,526
2026-03-13 2026-03-11 S Sale
1.0
Rowland Thomas Andrew

SVP, HEAD - ESTABLISHED BRANDS

Officer
4,772 -11.0%
74.91
US$357,471 		4,772 -11.0% 74.91 US$357,471
2026-03-10 2026-03-09 PlS Planned sale
2.5
Mutz Christopher

HEAD OF RARE DISEASE

Officer
3,602 -3.7%
74.18
US$267,196 		3,602 -3.7% 74.18 US$267,196
2026-03-10 2026-03-09 PlS Planned sale
2.4
Davis Krista

SVP, CHIEF HR OFFICER

Officer
5,087 -8.9%
74.13
US$377,099 		5,087 -8.9% 74.13 US$377,099
2026-03-10 2026-03-06 PlS Planned sale
2.5
Mutz Christopher

HEAD OF RARE DISEASE

Officer
2,121 -2.0%
74.22
US$157,421 		2,121 -2.0% 74.22 US$157,421
2026-03-10 2026-03-06 PlS Planned sale
2.4
Davis Krista

SVP, CHIEF HR OFFICER

Officer
1,485 -2.5%
75.00
US$111,375 		1,485 -2.5% 75.00 US$111,375
2026-03-05 2026-03-05 S Sale
2.8
CAREY STEPHEN P.

SVP & CFO

Officer
4,000 -2.1%
75.56
US$302,240 		4,000 -2.1% 75.56 US$302,240
2026-03-05 2026-03-05 S Sale
2.8
CAREY STEPHEN P.

SVP & CFO

Officer
3,312 -1.7%
75.42
US$249,791 		3,312 -1.7% 75.42 US$249,791
2026-03-05 2026-03-05 PrS Proposed sale
2.8
STEPHEN P CAREY

Officer

Officer
7,312
75.49
US$552,017 		7,312 75.49 US$552,017
2026-03-04 2026-03-03 S Sale
3.2
Gutwerg Ori

SVP, GENERICS

Officer
2,060 -2.4%
76.50
US$157,590 		2,060 -2.4% 76.50 US$157,590
2026-03-03 2026-03-03 S Sale
3.8
Walsh Patrick D
Non-Executive Director
6,000 -10.3%
74.23
US$445,380 		6,000 -10.3% 74.23 US$445,380
2026-03-03 2026-03-03 PrS Proposed sale
3.8
PATRICK WALSH

Director

Non-Executive Director
6,000
74.23
US$445,390 		6,000 74.23 US$445,390
2026-03-04 2026-03-02 PlS Planned sale
2.5
Mutz Christopher

HEAD OF RARE DISEASE

Officer
417 -0.4%
74.00
US$30,858 		417 -0.4% 74.00 US$30,858
2026-02-23 2026-02-20 PlS Planned sale
2.5
Mutz Christopher

HEAD OF RARE DISEASE

Officer
5,323 -5.9%
78.02
US$415,300 		5,323 -5.9% 78.02 US$415,300
2026-02-23 2026-02-20 PlS Planned sale
2.4
Davis Krista

SVP, CHIEF HR OFFICER

Officer
1,730 -3.4%
77.99
US$134,923 		1,730 -3.4% 77.99 US$134,923
2026-02-23 2026-02-19 PlS Planned sale
2.4
Davis Krista

SVP, CHIEF HR OFFICER

Officer
2,084 -3.9%
77.53
US$161,573 		2,084 -3.9% 77.53 US$161,573
2026-02-17 2026-02-13 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
500 -0.7%
76.80
US$38,400 		500 -0.7% 76.80 US$38,400
2026-02-17 2026-02-12 PlS Planned sale
2.5
Mutz Christopher

HEAD OF RARE DISEASE

Officer
7,032 -7.1%
76.55
US$538,300 		7,032 -7.1% 76.55 US$538,300
2026-01-14 2026-01-13 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
500 -0.7%
84.33
US$42,165 		500 -0.7% 84.33 US$42,165
2025-12-19 2025-12-18 PlS Planned sale
2.4
Davis Krista

SVP, CHIEF HR OFFICER

Officer
1,622 -2.7%
82.40
US$133,653 		1,622 -2.7% 82.40 US$133,653
2025-12-12 2025-12-12 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
400 -0.5%
82.32
US$32,928 		400 -0.5% 82.32 US$32,928
2025-12-09 2025-12-05 PrS Proposed sale
3.4
RENATE PLAWNER TANNENBAUM 2024 RV TRUST

Director

Non-Executive Director
1,800
81.15
US$146,070 		1,800 81.15 US$146,070
2025-12-09 2025-12-05 S Sale
3.4
TANNENBAUM RENEE P
Non-Executive Director
1,800 -6.7%
81.15
US$146,070 		1,800 -6.7% 81.15 US$146,070
2025-11-17 2025-11-13 S Sale
3.8
Walsh Patrick D
Non-Executive Director
8,643 -12.3%
86.88
US$750,904 		8,643 -12.3% 86.88 US$750,904
2025-11-14 2025-11-13 S Sale
3.2
Gassert Chad

SVP - CORP. DEV. & STRATEGY

Officer
94 -0.1%
88.00
US$8,272 		94 -0.1% 88.00 US$8,272
2025-11-14 2025-11-13 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
400 -0.5%
87.27
US$34,908 		400 -0.5% 87.27 US$34,908
2025-11-13 2025-11-13 PrS Proposed sale
3.8
PATRICK WALSH

Director

Non-Executive Director
8,643
86.88
US$750,914 		8,643 86.88 US$750,914
2025-11-14 2025-11-12 S Sale
3.2
Gassert Chad

SVP - CORP. DEV. & STRATEGY

Officer
14,642 -8.5%
89.07
US$1,304,163 		14,642 -8.5% 89.07 US$1,304,163
2025-10-14 2025-10-13 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
400 -0.5%
90.09
US$36,036 		400 -0.5% 90.09 US$36,036
2025-09-22 2025-09-19 PlS Planned sale
2.4
Davis Krista

SVP, CHIEF HR OFFICER

Officer
1,000 -1.6%
98.04
US$98,040 		1,000 -1.6% 98.04 US$98,040
2025-09-15 2025-09-12 PlS Planned sale
Cook Meredith

SR. VP, GENERAL COUNSEL & SEC.

Officer
400 -0.5%
98.42
US$39,368 		400 -0.5% 98.42 US$39,368
2025-09-04 2025-09-03 S Sale
2.9
Pera Antonio R
Non-Executive Director
7,292 -24.3%
94.94
US$692,302 		7,292 -24.3% 94.94 US$692,302
2025-09-03 2025-09-03 PrS Proposed sale
2.9
ANTONIO R PERA

Director

Non-Executive Director
7,292
94.94
US$692,270 		7,292 94.94 US$692,270
2025-08-26 2025-08-25 S Sale
2.5
Leonard Matthew J
Non-Executive Director
2,528 -26.9%
90.62
US$229,087 		2,528 -26.9% 90.62 US$229,087
2025-08-25 2025-08-25 PrS Proposed sale
2.5
MATTHEW LEONARD

Director

Non-Executive Director
2,528
90.62
US$229,076 		2,528 90.62 US$229,076
2025-08-25 2025-08-22 S Sale
2.4
Davis Krista

SVP, CHIEF HR OFFICER

Officer
1,763 -2.7%
91.10
US$160,609 		1,763 -2.7% 91.10 US$160,609
2025-08-22 2025-08-21 S Sale
3.0
Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

Executive Director
52,988 -10.9%
90.44
US$4,792,235 		52,988 -10.9% 90.44 US$4,792,235
2025-08-21 2025-08-21 PrS Proposed sale
3.0
Shanmugam Muthusamy

Officer

Officer
52,988
90.44
US$4,792,058 		52,988 90.44 US$4,792,058
2025-08-22 2025-08-20 S Sale
3.0
Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

Executive Director
47,012 -8.8%
90.27
US$4,243,773 		47,012 -8.8% 90.27 US$4,243,773
2025-08-20 2025-08-20 PrS Proposed sale
3.0
Shanmugam Muthusamy

Officer

Officer
47,012
90.27
US$4,243,703 		47,012 90.27 US$4,243,703
2025-08-20 2025-08-20 PrS Proposed sale
2.9
ANTONIO R PERA

Director

Non-Executive Director
5,421
89.73
US$486,407 		5,421 89.73 US$486,407
2025-08-20 2025-08-20 S Sale
2.9
Pera Antonio R
Non-Executive Director
5,421 -15.3%
89.73
US$486,426 		5,421 -15.3% 89.73 US$486,426
2025-08-20 2025-08-18 S Sale
2.7
Thoma Jeanne
Non-Executive Director
14,675 -38.5%
88.87
US$1,304,167 		14,675 -38.5% 88.87 US$1,304,167
2025-08-20 2025-08-18 S Sale
2.7
Thoma Jeanne
Non-Executive Director
6,865 -15.3%
89.76
US$616,202 		6,865 -15.3% 89.76 US$616,202
2025-08-19 2025-08-18 PrS Proposed sale
2.7
JEANNE THOMA

Director; 10% Stockholder

Non-Executive Director Large shareholder
14,675
88.87
US$1,304,170 		14,675 88.87 US$1,304,170
2025-08-18 2025-08-18 PrS Proposed sale
2.7
JEANNE A THOMA

Director

Non-Executive Director
6,865
89.76
US$616,224 		6,865 89.76 US$616,224
2025-08-18 2025-08-18 PrS Proposed sale
2.5
MATTHEW LEONARD

Director

Non-Executive Director
6,937
88.17
US$611,644 		6,937 88.17 US$611,644
2025-08-18 2025-08-18 PrS Proposed sale
AMPERSAND 2020 LIMITED PARTNERSHIP

Director

Non-Executive Director
29,580
88.32
US$2,612,420 		29,580 88.32 US$2,612,420
2025-08-18 2025-08-18 S Sale
2.5
Leonard Matthew J
Non-Executive Director
6,937 -42.5%
88.17
US$611,635 		6,937 -42.5% 88.17 US$611,635
2025-08-18 2025-08-15 S Sale
3.8
Walsh Patrick D
Non-Executive Director
9,000 -11.4%
89.05
US$801,450 		9,000 -11.4% 89.05 US$801,450
2025-08-18 2025-08-15 S Sale
3.0
Shanmugam Muthusamy

HEAD OF R&D, COO-NOVITIUM OPS

Executive Director
52,990 -9.1%
87.15
US$4,618,078 		52,990 -9.1% 87.15 US$4,618,078
Explore more

More insider trading research around ANI Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America